The La Jolla Institute of Immunology (LJII) licensed the Seqster Research Portal (SRP) health data management platform to connect patients, clinicians and researchers to support the development of personalized treatments for asthma. The 3-year deal supports LJII participation in a $6.9 million asthma study funded by the National Heart, Lung and Blood Institute. Up to 5,000 study participants will be involved in contributing to the real-time collection of longitudinal health records data augmenting a quest to identify personalized asthma treatments and ultimately finding an asthma cure.
Forming a PrecISE Network Clinical Center
The National Institute of Health’s National Heart, Lung and Blood Institute (NHLBI) has invested $6.9 million into an asthma study ultimately establishing 10 PrecISE Network Clinical Centers nationwide. Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network is a network of leading academic institutions and physician-scientists formed to discover personalized treatments for patients with severe asthma.
What is the Seqster SRP product?
Recently noted in a press release, Seqster SRP, a software-as-a-service (SaaS) healthcare platform, will support LJII efforts to integrate electronic health records (EHR), individual genomic profiles (DNA) and personal health device data, such as wearables of fitness devices. The vendor’s portal is intended to streamline the study recruitment and consent process directly importing “Real-World Data (RWD) and Real-World Evidence (RWE) with the chain of custody.
Vendor Selection: Support the Mission of the PrecISE Study
Stephen Wilson, Ph.D., Executive Vice President and Chief Operating Officer of LJII noted: “We needed a scalable and robust platform that supports rapid person-centric data aggregation as well as real-time collection of longitudinal health records data to build this important and ambitious research cohort.” He continued in positive recognition of their vendor selection “The Seqster Research Portal is the only platform that will allow our PrecISE study participants to instantly collect and share medical records, genomic and device data with our researchers from anywhere in the country in a secure and transparent way while maintaining data ownership.”
Who is Seqster?
Seqster is a privately-held, San Diego-based startup launched in 2018 to ultimately drive data ownership to unlock better health for today and the future. The venture launched its secure platform after raising $4 million in seed financing–they will seek an A round for expansion with powerful milestones and achievements ongoing. Positioned to “break down data silos” the venture’s leadership seeks to drive opportunity for health systems, payers or researchers to import, upload and incorporate valuable health data from distinct sources.
Last year it integrated its health data management platform with the MyGenRank app of Scripps Research Translational Institute (SRTI), through collaboration to promote better healthcare decisions by app users through tracking of medications and lifestyle modifications. MyGeneRank is designed to allow individuals with genetic data from 23andMe to obtain an estimated genetic risk score for coronary artery disease.
Seqster recently declared in the LJII press release that the platform now connects users to more than 3,000 healthcare providers and over 100,000 hospitals and clinics nationwide. CEO and Co-founder Ardy Arianpour, a young, dynamic and successful entrepreneur, has been active in a number of Southern California-based genetic testing market ventures, launching several clinical and consumer-based genetic tests products. Out of UC Irvine, he was the 2019 recipient of Top 40 Healthcare Transformer and SDBJ 40 under 40.
La Jolla Institute
Launched in 1988, LJII is located in UC San Diego’s Research Park in what could be considered one of the most attractive places to work in America. The institute focuses research on immunology and immune system diseases and employs 25 to 30 faculty members and more than 300 employees. With a collaborative and dynamic culture, LJII forms many partnerships within the local San Diego research community and beyond. Its biomedical facility covers 145,000 square feet inclusive of specialized research rooms for all aspects of molecular and cellular biology.
The Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) is a clinical study sponsored by NHLBI. PrecISE’s physician-scientists are dedicated to researching better treatments for living with severe asthma.
By using precise medicine strategies and methods to support research into severe asthma, investigators seek to identify subgroups of patients who share similar characteristics, for example, patients with certain genetic variation or patients with high number of blood eosinophils (a type of white blood cell that may contribute to asthma by causing inflammation in the patient’s respiratory system).
With over 30 locations across the U.S., Canada, and the UK, a map and list of Principal Investigator by participating research institution is listed here. UC San Diego’s Principal Investigator is Sonia Jain, for example.
Call to Action: Interested in precision-based research for severe asthma? The PrecISE study should be on your list for monitoring or even engagement. Interested in a platform to collect “Real-World Data” for a study? At least take a look at Seqster—it looks like interesting technology.